{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+sham+treatment&page=17",
    "query": {
      "intervention": "Placebo and sham treatment",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 27749,
    "total_pages": 2775,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+sham+treatment&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+sham+treatment&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T04:18:57.098Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04442347",
      "title": "Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ornithine Transcarbamylase Deficiency"
      ],
      "interventions": [
        {
          "name": "ARCT-810",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Arcturus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-11-03",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 8,
      "location_summary": "Gainesville, Florida • Minneapolis, Minnesota • New York, New York + 5 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04442347"
    },
    {
      "nct_id": "NCT04468958",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV2"
      ],
      "interventions": [
        {
          "name": "SAB-185",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-07-01",
      "completion_date": "2020-12-23",
      "has_results": false,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 3,
      "location_summary": "Wichita, Kansas • Syracuse, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04468958"
    },
    {
      "nct_id": "NCT02161458",
      "title": "Escitalopram Effects on CSF Amyloid Beta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Amyloid Beta Protein"
      ],
      "interventions": [
        {
          "name": "Escitalopram 20mg for 2 weeks",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram 20mg for 8 weeks",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram 30mg for 8 weeks",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 98,
      "start_date": "2014-06",
      "completion_date": "2019-01",
      "has_results": true,
      "last_update_posted_date": "2020-04-09",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02161458"
    },
    {
      "nct_id": "NCT01272258",
      "title": "A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "PRO 140",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2013-12",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2017-02-02",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272258"
    },
    {
      "nct_id": "NCT01162109",
      "title": "Zinc Therapy in Critical Illness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Sepsis"
      ],
      "interventions": [
        {
          "name": "Zinc sulfate",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2010-09",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01162109"
    },
    {
      "nct_id": "NCT00509132",
      "title": "A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "trodusquemine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genaera Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2007-05",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2008-01-09",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509132"
    },
    {
      "nct_id": "NCT05562063",
      "title": "Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Sotagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Juan Badimon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2022-10-26",
      "completion_date": "2025-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05562063"
    },
    {
      "nct_id": "NCT05912387",
      "title": "Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis",
        "Inflammatory Bowel Diseases"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2023-05-31",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05912387"
    },
    {
      "nct_id": "NCT03583606",
      "title": "A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Disease",
        "Immunisation"
      ],
      "interventions": [
        {
          "name": "ChAd3-EBO-Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA Multi-Filo Ebola Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-11-12",
      "completion_date": "2020-01-14",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583606"
    },
    {
      "nct_id": "NCT02221947",
      "title": "Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Bryostatin 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurotrope Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-10-14T04:18:57.098Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02221947"
    }
  ]
}